Abstract

While some potential biomarkers for ocular diseases have been reported, it is difficult to select a single biomarker that is most important in each ocular disease. After reviewing multiple biomarker studies conducted on small sample subgroups, we concluded that newer analysis techniques may result in different and more specific findings. While progress has been made in developing various omics studies, studies comparing tears of normal and diseased eyes are still lacking. Preliminary omics studies suggest the importance of further studies aimed at identifying potential ocular-associated lipid, non-lipid/protein, and protein biomarkers. In addition, combining potential biomarkers might be a good strategy for the diagnosis and assessment of ocular diseases.